HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.

Abstract
N-[3-[[[(1S)-4-(5-Amino-2-pyridinyl)-1-[[4-difluoromethylene)-1-piperidinyl]carbonyl]butyl]amino]sulfonyl][1,1'-biphenyl]-2-yl]acetamide hydrochloride (SSR182289A) is a novel, potent, and selective thrombin inhibitor. We have examined the antithrombotic properties of SSR182289A administered by i.v. and p.o. routes in several different animal thrombosis models in comparison with reference antithrombotic agents. Oral administration of SSR182289A produced dose-related antithrombotic effects in the following models; rat venous thrombosis (ED(50) 0.9 mg/kg p.o.), rat silk thread arterio-venous (AV) shunt (ED(50) 3.8 mg/kg p.o.), rat thromboplastin-induced AV shunt (ED(50) 3.1 mg/kg p.o.), rat carotid artery thrombosis (ED(200) 5.9 mg/kg p.o.), and rabbit venous thrombosis (ED(50) 7.5 mg/kg p.o.). Administered as an i.v. bolus, SSR182289A showed antithrombotic activity in the above models with ED(50)/ED(200) values in the range of 0.2 to 1.9 mg/kg i.v. SSR182289A increased rat tail transection bleeding time at doses > or =10 mg/kg p.o. In the rat thromboplastin-induced AV shunt model, SSR182289A 10 mg/kg p.o. produced marked antithrombotic effects at 30, 60, 120, and 240 min after administration. Hence, SSR182289A demonstrates potent oral antithrombotic properties in animal venous, AV-shunt, and arterial thrombosis models.
AuthorsJ Lorrain, L Millet, I Lechaire, S Lochot, P Ferrari, C Visconte, M Sainte-Marie, C Lunven, C N Berry, P Schaeffer, J-M Herbert, S E O'Connor
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 304 Issue 2 Pg. 567-74 (Feb 2003) ISSN: 0022-3565 [Print] United States
PMID12538808 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Aminopyridines
  • Fibrinolytic Agents
  • N-(3-((((4-(5-amino-2-pyridinyl)-1-((4-difluoromethylene)-1-piperidinyl)carbonyl)butyl)amino)sulfonyl)(1,1'-biphenyl)-2-yl) acetamide
  • Sulfonamides
  • Thrombin
Topics
  • Administration, Oral
  • Aminopyridines (pharmacology, therapeutic use)
  • Animals
  • Bleeding Time (statistics & numerical data)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Fibrinolytic Agents (pharmacology, therapeutic use)
  • Male
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley
  • Sulfonamides (pharmacology, therapeutic use)
  • Thrombin (antagonists & inhibitors, physiology)
  • Thrombosis (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: